LB Pharmaceuticals reports Q3 2026 results, affirms 1H 2027 data for schizophrenia drugNov 5Quarterly updateLB Pharmaceuticals Inc.LB-102
LB Pharmaceuticals names Joseph Miller as chief financial officerSep 3PeopleLB Pharmaceuticals Inc.LB-102
LB Pharmaceuticals moves up NOVA-2 schizophrenia readout to first half of 2027Aug 11Quarterly updateLB Pharmaceuticals Inc.LB-102
LB Pharmaceuticals sets $150 million private placement of stock and warrantsJul 29FinancingLB Pharmaceuticals Inc.LB-102
LB Pharmaceuticals moves up NOVA-2 schizophrenia trial readout to first half of 2027Jul 22Clinical readoutLB Pharmaceuticals Inc.LB-102